|
Aug 9
|
CorMedix Second Quarter 2025 Earnings: Beats Expectations
|
|
Aug 8
|
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi
|
|
Aug 8
|
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
|
|
Aug 8
|
Cormedix Inc (CRMD) Q2 2025 Earnings Call Highlights: Strategic Acquisition and Positive ...
|
|
Aug 8
|
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues
|
|
Aug 8
|
CorMedix signs agreement to acquire Melinta for $300m
|
|
Aug 7
|
Sector Update: Health Care Stocks Decline Late Afternoon
|
|
Aug 7
|
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
|
|
Aug 7
|
NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View
|
|
Aug 7
|
CorMedix to Buy Melinta Therapeutics for $300 Million
|
|
Aug 7
|
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y
|
|
Aug 7
|
Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
|
|
Aug 7
|
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates
|
|
Aug 7
|
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum
|
|
Aug 7
|
CorMedix: Q2 Earnings Snapshot
|
|
Aug 7
|
Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership
|
|
Aug 7
|
CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings
|
|
Aug 7
|
Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
|
|
Aug 6
|
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark
|
|
Aug 6
|
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
|